Medical Oncologist
Targeted treatment
CDK4/6 inhibitors in breast cancer: the full picture
CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib block proteins that hormone-sensitive breast cancer cells need to divide. Given with hormone therapy, they are a standard first treatment for metastatic HR-positive, HER2-negative breast cancer. This page explains them in general terms.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- What are CDK4/6 inhibitors and when are they used?
- The three CDK4/6 inhibitors, in general terms
- The side effects most worth knowing about
- The vocabulary, in plain language
- What CDK4/6 inhibitors can and cannot do
- How CDK4/6 inhibitors are used when cancer has spread
- Living day to day on a CDK4/6 inhibitor
- How oncologists choose between the three drugs
- Checks usually done before treatment begins
- What people assume about CDK4/6 inhibitors
- Common questions about CDK4/6 inhibitors
The short answer
What are CDK4/6 inhibitors and when are they used?
CDK4/6 inhibitors are targeted tablets that block two proteins, CDK4 and CDK6, which hormone-sensitive breast cancer cells rely on to move through the cycle of dividing. The three used in breast cancer are palbociclib, ribociclib and abemaciclib. They are always given together with hormone therapy, never on their own. In metastatic hormone receptor positive, HER2-negative breast cancer, this combination is a standard first treatment that keeps the cancer controlled for longer, and for ribociclib and abemaciclib has also been shown to help women live longer. Ribociclib and abemaciclib are also used after surgery for some early breast cancers at higher risk of returning.
How they work
Oestrogen switches on signals that activate CDK4 and CDK6, which push the cell to copy its DNA and divide. Blocking these proteins acts as a brake on cell division, while hormone therapy cuts off the oestrogen signal. Together they are far more effective than hormone therapy alone.
Who they are for
Women and men with hormone receptor positive, HER2-negative breast cancer, either metastatic or early-stage with higher-risk features. They are not used for triple negative or HER2-positive cancers outside trials.
Who may not be suitable
People with certain heart rhythm problems, significant liver disease, very low blood counts, or those taking medicines that interact strongly. Your oncologist chooses the drug that best suits your health.
This page gives general information only. Your treatment is planned by your oncologist.Side by side
The three CDK4/6 inhibitors, in general terms
Drug
Key features
Palbociclib
Three weeks on, one off; low white counts main effect
Ribociclib
Three weeks on, one off; needs ECG and liver checks
Abemaciclib
Taken continuously; loose motions common early
Metastatic disease
All three used with hormone therapy
Early breast cancer after surgery
Abemaciclib and ribociclib in selected women
Side effects
The side effects most worth knowing about
Most are manageable with monitoring and dose adjustments.
Low white blood cells
Very common with palbociclib and ribociclib. Usually causes no symptoms and rarely leads to serious infection.
Loose motions
Common with abemaciclib, especially in the first weeks. Anti-diarrhoea medicine and fluids usually control it.
Start treatment as soon as it begins.Liver and heart rhythm changes
Ribociclib can affect liver tests and heart rhythm, so blood tests and ECGs are done regularly.
Tiredness and other effects
Fatigue, mild hair thinning, mouth soreness and, rarely, lung inflammation.
Report promptly
- Fever or chills
- Loose motions that do not settle
- New cough or breathlessness
Words you will hear
The vocabulary, in plain language
- CDK4 and CDK6
- Proteins that help cells move through division.
- Cell cycle
- The series of steps a cell goes through to copy itself and divide.
- Neutrophils
- White blood cells that fight infection.
- ECG
- A heart tracing used to check rhythm.
- Progression-free survival
- How long the cancer stays under control on treatment.
- Overall survival
- How long people live after starting treatment.
Being straight with you
What CDK4/6 inhibitors can and cannot do
CDK4/6 inhibitors have transformed treatment for hormone-sensitive metastatic breast cancer. Many women keep their cancer controlled for years on this combination. They do not make metastatic cancer go away for good, and most cancers eventually find a way around them.
Dose reductions are common and acceptable
Many women need a lower dose. Studies suggest this does not reduce how well the treatment works, so there is no need to push through severe side effects.
The drugs are not identical
Although they share a mechanism, the three drugs differ in schedule, side effects and evidence in different settings. Your oncologist chooses the one that best matches your situation.
Cost and access
These medicines are expensive in India, though prices and support programmes change. Ask early about cost and assistance.
What this page cannot tell you
It cannot tell you which drug suits you or how long it will work. Ask your oncologist to explain your options.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
In metastatic disease
How CDK4/6 inhibitors are used when cancer has spread
For most women with newly diagnosed hormone receptor positive, HER2-negative metastatic breast cancer, a CDK4/6 inhibitor with hormone therapy is now the preferred first treatment, unless the cancer needs the faster response of chemotherapy.
Partner hormone therapy
The CDK4/6 inhibitor is combined with an aromatase inhibitor, or with fulvestrant if the cancer has grown on an aromatase inhibitor before. Premenopausal women also receive ovarian suppression.
How long treatment lasts
Treatment usually continues for as long as scans show the cancer is controlled and side effects are manageable, which for many women is years.
When it stops working
If the cancer grows, the next treatment depends on mutation tests, previous treatments and how the cancer is behaving. Options may include other targeted drugs with hormone therapy, newer oral hormone treatments, antibody-drug conjugates or chemotherapy.
Daily life
Living day to day on a CDK4/6 inhibitor
Most women take these tablets at home and continue many of their usual activities, with some adjustments.
Blood tests and reviews
Tests are frequent at first, often every two weeks, then usually monthly once the dose is settled.
Medicines and foods to check
Some antibiotics, antifungals, heart medicines, herbal products and grapefruit can interact. Always check before starting anything new.
Infection sense
Serious infections are uncommon, but good hand hygiene and prompt reporting of fever are sensible, especially when counts are low.
Choosing a drug
How oncologists choose between the three drugs
Because the three CDK4/6 inhibitors work in a similar way, the choice often comes down to practical matters and how each fits with your health and daily life.
Your heart and liver
Ribociclib can lengthen a measure on the heart tracing called the QT interval and affect liver tests, so it may be less suitable for people with certain heart rhythm problems or those taking other medicines that affect heart rhythm. Palbociclib and abemaciclib have fewer heart rhythm concerns.
Your bowels
Abemaciclib causes loose motions more often, especially early on. Women with existing bowel problems, or who would find frequent loose motions very hard to manage, may prefer another drug.
Blood counts
Palbociclib and ribociclib lower white cells more often, which means regular blood tests and occasional dose pauses. Abemaciclib affects counts less.
Evidence, availability and cost
The strength of evidence in your particular situation, whether a drug is available at your centre, and the cost, including support programmes, also influence the decision.
Before starting
Checks usually done before treatment begins
A few baseline tests make treatment safer and give a reference point for later.
Blood tests
A full blood count and liver and kidney function tests are checked before the first dose.
A full medicine review
Your team checks every medicine and supplement you take, because some common antibiotics, antifungals and herbal products change levels of these drugs in the blood.
Heart tracing
An ECG is usually done before ribociclib, and repeated in the early weeks.
Commonly believed
What people assume about CDK4/6 inhibitors
CDK4/6 inhibitors are chemotherapy.
They are targeted tablets with a different mechanism and usually less hair loss and sickness than chemotherapy.
They can be taken without hormone therapy.
They are always given with hormone therapy. The combination is what makes them work.
A low white count means I have a serious infection risk.
Low counts are expected and rarely cause serious infection with these drugs, though fever should always be reported.
A lower dose will not work as well.
Studies suggest dose reductions for side effects keep the benefit.
Questions we are asked
Common questions about CDK4/6 inhibitors
Which CDK4/6 inhibitor is best?
There is no single best drug for everyone. The choice depends on your setting, health, other medicines, side effect concerns, availability and cost.
Will I lose my hair?
Some thinning can occur, but significant hair loss is uncommon.
Can men take CDK4/6 inhibitors?
Yes, men with hormone-sensitive, HER2-negative metastatic breast cancer can benefit.
What if I miss a dose?
Do not take extra. Take the next dose at the usual time and tell your team.
Can I travel?
Often yes, with planning around blood tests and carrying enough tablets.
Are generics available in India?
Availability changes. Ask your oncologist about current options and support programmes.
Is pregnancy safe during treatment?
No. Effective contraception is needed during treatment and for a period afterwards.
Where can I read about my own drug?
Your oncology team will give you written information about your treatment. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- European Society for Medical Oncology — Metastatic breast cancer clinical practice guideline
- National Cancer Institute — Breast cancer treatment (PDQ)
- Cancer Research UK — Targeted cancer drugs for breast cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.